Features of the course of COVID-19 in patients with sarcoidosis

Abstract

Concomitant pathology is a risk factor for severe COVID-19. Bilateral changes characteristic of sarcoidosis on CTscan can also occur with coronavirus infection. <b>The purpose of the study:</b> based on our own data to study the features of the course of a new coronavirus infection in patients with lung sarcoidosis. <b>Materials and methods:</b> 47 patients have been under observation which accounted for 22.4% of the total number of observed patients with sarcoidosis. Concomitant pathology: cardiovascular system - 24.9%, gastrointestinal tract pathology - 23.3%, COPD and bronchial asthma in 11.7%, diabetes mellitus in 5.25%. As a basic therapy, 74.5% received GCS, 5.2% - methotrexate, 16.2% - GCS +methotrexate. In addition, 32% took vitamin E and 19.8% - pentoxifylline. <b>Results and discussion:</b> The average age of patients is 37.2±3.4 (men 12, women 35). In 8 patients - pneumonia was not detected; in 21 patients (CT stage 1) SpO2 95.2± 2.4%, in 15 patients (CT stage 2) SpO2 86.0± 4.5%, in 4 patients (CT stage 3) COVID-19 had a severe SpO2 68.1± 7.3%, which required treatment in the intensive care unit. Blood parameters: IL-6 – 94.3±7.8 (N less than 3.4 ng/ml), CRP 103.4±8.9 (N 0-5 mg/L), ACE 82.3±7.3 (N 8-52 units/L), D-dimer 485±20.8 (N less than 442 ng/ml), ferritin 643.4±10.7 (N 28-365 ng/ml), GGT 104.5±3.7 (N 1-55 Units/L), procalcitonin 0.17 ± 0.01 (N less than 0.1ng/ml). <b>Conclusions:</b> based on the data obtained, a severe course of COVID-19 was noted in 6.38% of patients with sarcoidosis, the course of moderate severity in 32%. The factors contributing to the severe course include the use of cytostatics and GCS.